2021
O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES
Ragazzo T, Garcia-Tsao G, Mazo D, Ziteli P, Oliveira C, Singer J, Carrilho F, Pessoa M. O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES. Annals Of Hepatology 2021, 24: 100493. DOI: 10.1016/j.aohep.2021.100493.Peer-Reviewed Original ResearchLiver stiffness measurementF3/F4Viral eliminationLiver fibrosisF0-1Advanced liver fibrosis/cirrhosisLiver fibrosis/cirrhosisChronic liver diseaseFibrosis/cirrhosisNon-invasive testsNon-invasive assessmentHCV cureAntiviral therapyClinical outcomesLiver diseaseHepatic fibrosisClinical usefulnessPatientsPredictive valueRelevant outcomesDecompensationLarger studyFibrosisLSM increaseStiffness measurement
2017
THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation
Winters A, Luedtke S, Moreland A, Jangouk P, Weng G, Silveira M, Davitkov P, Duarte-Rojo A, Cheung R, Garcia-Tsao G, Falck-Ytter Y, Branch A, Bräu N. THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation. Journal Of Hepatology 2017, 66: s280. DOI: 10.1016/s0168-8278(17)30876-0.Peer-Reviewed Original Research
2012
Sa1091 Hepatitis C (HCV) Antiviral Therapy is Feasible in Patients With Active Substance use (SU) and Mental Illness (MI) and is More Likely to Occur in Those Who Receive Education Class
Bari K, Augustin S, Eggers C, Hashem H, Desai M, Shea M, Wongcharatrawee S, Lim J, Garcia-Tsao G. Sa1091 Hepatitis C (HCV) Antiviral Therapy is Feasible in Patients With Active Substance use (SU) and Mental Illness (MI) and is More Likely to Occur in Those Who Receive Education Class. Gastroenterology 2012, 142: s-967. DOI: 10.1016/s0016-5085(12)63744-5.Peer-Reviewed Original Research
2005
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†
Chainuvati S, Khalid S, Kancir S, Shea M, Edwards J, Sernyak M, Wongcharatrawee S, Garcia‐Tsao G. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†. Journal Of Viral Hepatitis 2005, 13: 235-241. PMID: 16611189, DOI: 10.1111/j.1365-2893.2005.00681.x.Peer-Reviewed Original ResearchConceptsCompletion of therapyVirological responsePatient demographicsSubstance useAntiviral therapyMental illnessHepatitis C virus infectionLiver disease characteristicsC virus infectionNIH Consensus ConferenceType of therapyLiver clinicSVR ratesHCV RNAPositive patientsRelative contraindicationTherapy completionTreatment patternsLiver diseaseTreatment eligibilityDisease characteristicsPatient populationPoor adherenceVirus infectionConsensus conference
2002
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
Burroughs A, Groszmann R, Bosch J, Grace N, Garcia-Tsao G, Patch D, Garcia-Pagan J, Dagher L. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002, 50: 425. PMID: 11839726, PMCID: PMC1773121, DOI: 10.1136/gut.50.3.425.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientChronic hepatitis CVenous pressure gradientHepatitis CAntiviral therapyEnd pointChronic hepatitis C.Major healthcare problemBest end pointHepatitis C.HVPG measurementTherapeutic benefitTherapeutic evaluationTherapyHealthcare problemPatientsPressure gradientResponse